




## Guidelines for Preparing Abstracts: For Authors

### General requirements:

1. Abstracts must be original and must not have been previously published elsewhere.
2. All abstracts will be reviewed by symposium scientific review committee and only accepted abstracts can be presented at the symposium as oral / e-poster / poster.
3. All accepted and presented abstracts at the symposium will be published in **BioMed Central Journal, BMC Infectious Diseases**  Springer. The corresponding author should ensure that all named authors should agree to the submission of the abstract for publication.
4. Spellings within any one abstract should be either US English or UK English, but not a mixture.
5. The word limit of the abstract main text should not exceed **250 words** excluding title, authors and affiliations.
6. To be acceptable, abstracts shall contain a concise statement of the research. No tables, figures and references are allowed in the abstract.
7. Research involving human subjects must have been approved by an appropriate ethics committee/IRB. Abstracts that do not contain relevant ethics and consent statements will not be considered for evaluation.
8. The abstract review committee of the ISSHID 2019 and the journal **BMC Infectious Diseases** reserves full rights for editing and publishing the abstracts.
9. Apart from regular research abstract, **Case Reports** are also invited with well-described reports of exceptional or unusual cases. Case reports should make a contribution to medical knowledge and must have educational value or highlight the need for a change in clinical practice or diagnostic/prognostic approaches.
10. The abstract should be submitted in any one of the following categories: **Basic Science, Clinical Science, Case Reports, Social & Behavioural Science, Epidemiology/Public Health and Translational Research.**
11. If the abstract contains details relating to individual participants (for example, a Case Report), written informed consent for the publication of these details must be obtained from the participants and a statement to this effect should appear at the end of the abstract. The journal **BMC Infectious Diseases** guidelines for consent statements can be found here: <http://www.biomedcentral.com/about/editorialpolicies>. If the patient is deceased, consent for publication should be obtained from the next of kin; if the patient is under 16, consent should be obtained from the parent or guardian.
12. If the abstract reports the results from the human clinical trial, the trial registry, along with the unique identifying number (e.g. Trial registration: Current Controlled Trials ISRCTN37824458) should be listed at the end of the abstract. The Publisher supports prospective registration and numbering of randomized controlled trials (RCTs). Authors of reports of controlled trials of health care interventions must register their

trial in a suitable publicly accessible registry prior to submission. The trial registers that currently meet all of the ICMJE guidelines can be found at <http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/>.

## Abstract Categories

### A. Basic Science:

Virology, Bacteriology, Mycology and Parasitology  
Immunology and Host Immune Responses to Infection  
Pathogenesis: Human Studies and Animal Models  
Molecularbiology studies in infectious diseases  
Vaccines  
Diagnostics  
Pre-clinical studies  
Bioinformatics in Infectious Diseases  
*In silico* modeling and docking

### B. Clinical Science:

Natural history of infections and pathogenesis (eg. HIV, Sexually Transmitted Infections (STIs), viral hepatitis, TB infections and other opportunistic infections)  
Other clinical studies including cohort studies and human clinical trials  
Clinical interventions  
Clinical complications and treatment outcome  
Malignancies in infectious diseases  
Case reports

### C. Social & Behavioral Science:

Psycho-social issues in infectious diseases  
Behavioral issues in infectious diseases

### D. Epidemiology/Public Health:

Epidemiology of infectious diseases (Infectious Diseases in general population and high-risk groups)  
Prevention Interventions

### E. Translational Research:

Research related to health outcomes.eg. Diagnostic or Treatment interventions.

## Preparation of Abstracts:

**Title:** Use a short and concise title that indicates the content of the abstract.

**Authors:** Maximum of 10 authors could be listed. First name, middle initials if required, and surname with no full stop at the end. A comma should separate author names. Where authors are from a number of different institutions, the appropriate institution number from the affiliation list should be given as a number immediately after each author's name, e.g.: John Smith<sup>1</sup>, Susan Jones<sup>2</sup>

**Affiliations:** Affiliations should include department, institute, town and country. Where there are multiple affiliations, each should be listed as a separate paragraph. Each institute should appear in the order used against the author names (see above paragraph) and show the appropriate number, e.g.:

1 Department, University, Town, State, Post code, USA.

2 Department, University, Town, State, Post code, UK.

**Main text:** Should not be more than 250 words. Greek and other special characters may be included. If you are unable to reproduce a particular special character, please type out the name of the symbol in full. SI units should be used throughout (litre and molar are permitted, however). If web link (URL) is used in the text, both the title of the site and the URL should be provided in the following format: Mouse Tumour Biology Database [[http://tumor.informatics.jax.org/cancer\\_links.html](http://tumor.informatics.jax.org/cancer_links.html)]. Abbreviations should be used as sparingly as possible and should be defined when first used.

### Background

The context, a description of the problem and an objective of the study.

### Methods

How the study was performed and statistical tests used.

### Results

The main findings in summary form and with enough data should be provided to permit evaluation by reviewers.

### Conclusion

Summarize the findings and the conclusion should be your results driven. It is unacceptable to use statements such as "the results will be discussed".